Table 4.
Adjusted Cox hazards regression models (including last CD4 and last viral load as independent variables) for patients who used antiretroviral therapy (N = 1878 individuals)
| Tuberculosis | Esophageal candidiasis | Cerebral Toxoplamosis | PCP | |
|---|---|---|---|---|
| (N = 30) | (N = 10) | (N = 12) | (N = 8) | |
| HR (CI) | HR (CI) | HR (CI) | HR (CI) | |
| Gender-Risk | ||||
| Women | Ref. | Ref. | Ref. | Ref. |
| Heterosexual men | 0.82 (0.37–1.82) | 0.16 (0.02–1.39) | 1.10 (0.27–4.43) | 0.90 (0.17–4.73) |
| MSM | 0.49 (0.16–1.48) | 0.37 (0.06–2.24) | 0.34 (0.04–2.71) | 0.57 (0.08–4.09) |
| Age (per year) | 1.02 (0.98–1.06) | 0.94 (0.86–1.02) | 0.90 (0.82–0.99) | 1.07 (1.00–1.14) |
| Race/ethnicity | ||||
| White | Ref. | Ref. | Ref. | Ref. |
| Non-white | 0.90 (0.41–2.00) | 1.84 (0.35–9.51) | 0.53 (0.14–1.92) | 1.05 (0.21–5.19) |
| Educational level | ||||
| 0–8 years | 1.89 (0.70–5.12) | 1.05 (0.22–5.12) | 1.46 (0.34–6.33) | 0.44 (0.08–2.41) |
| 9+ years | Ref. | Ref. | Ref. | Ref. |
| Nadir CD4+ T lymphocyte (per 100 cells/mm3) | 0.88 (0.62–1.24) | 0.95 (0.50–1.79) | 1.17 (0.85–1.61) | 1.15 (0.73–1.83) |
| Last CD4+ Tlymphocyteª (per/100 cells/mm3) | 0.95 (0.80–1.13) | 0.87 (0.61–1.23) | 0.70 (0.49–0.99) | 1.09 (0.90–1.33) |
| Last HIV viral loadb | ||||
| <400 copies/mm3 | Ref. | Ref. | Ref. | Ref. |
| >400 copies/mm3 | 0.35 (0.08–1.56) | 4.45 (0.98–20.19) | 3.04 (0.73–12.58) | 2.57 (0.42–15.88) |
| Opportunistic illness at enrollment | 23.01 (9.44–56.09) | 15.52 (3.38–71.30) | 31.96 (8.31–123.88) | 21.83 (2.85–167.29) |
| Time under cART (per year) | 0.79 (0.63–0.99) | 0.71 (0.40–1.28) | 0.70 (0.44–1.12) | 0.60 (0.33–1.08) |
cART combination antiretroviral therapy, PCP Pneumocystis jiroveci pneumonia, HR hazard ratio, CI 95 % confidence interval, MSM men who have sex with men
ªData imputed for 333 individuals with missing last CD4
bData imputed for 368 individuals with missing last HIV viral load
Bold font implies statistically significant results assuming a 5 % significance threshold